WO2005111027A1 - Nouveau procede de synthese de derives de la 1,3,4,5 tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable - Google Patents
Nouveau procede de synthese de derives de la 1,3,4,5 tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable Download PDFInfo
- Publication number
- WO2005111027A1 WO2005111027A1 PCT/FR2005/000396 FR2005000396W WO2005111027A1 WO 2005111027 A1 WO2005111027 A1 WO 2005111027A1 FR 2005000396 W FR2005000396 W FR 2005000396W WO 2005111027 A1 WO2005111027 A1 WO 2005111027A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- ivabradine
- process according
- synthesis process
- Prior art date
Links
- 0 COc(cc(CC(*(CCC(*)*)C=C1)=O)c1c1)c1OC Chemical compound COc(cc(CC(*(CCC(*)*)C=C1)=O)c1c1)c1OC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one derivatives, and their application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid.
- the present invention relates to a method for synthesizing compounds of formula (I):
- R 1 and R 2 which are identical or different, each represent a linear or branched alkoxy group (C ⁇ -C 8 ), or together form with the carbon atom carrying them a 1,3-dioxane ring, 1,3 -dioxolane or 1,3-dioxepane.
- Ivabradine as well as its addition salts with a pharmaceutically acceptable acid, and more particularly its hydrochloride, have very interesting pharmacological and therapeutic properties, especially bradycardic properties, which render these compounds useful in the treatment or prevention of different clinical situations of myocardial ischemia such as angina pectoris, myocardial infarction and associated rhythm disorders, as well as in various pathologies including rhythm disorders, particularly supraventricular disorders.
- This method has the disadvantage of leading to ivabradine hydrochloride with a very low yield, less than 17% over all 3 stages.
- This very low yield is due in part to the poor yield of the catalytic hydrogenation step of the 1,3-dihydro-2H-3-benzazepin-2-one function of the compound of formula (V) in 1, 3,4 Corresponding 5-tetrahydro-2H-3-benzazepin-2-one.
- i and R 2 which may be identical or different, each represents a linear or branched alkoxy (Ci-C 8 ) group or, together with the carbon atom carrying them, form a 1,3-dioxane ring, 1,3 -dioxolane or 1,3-dioxepane,
- nonacidic solvents that can be used for the process of the invention, mention may be made, without limitation, of acetates, alcohols, preferentially ethanol, methanol or isopropanol, tetrahydrofuran, toluene, dichloromethane and xylene.
- catalysts that can be used for the process of the invention, mention may be made, without limitation, of palladium, platinum, nickel, ruthenium and rhodium, as well as their derivatives, in particular in supported form or in the form of oxides.
- the preferred catalyst is palladium on carbon.
- the temperature of the hydrogenation reaction of the compound of formula (VI) is preferably between 20 and 100 ° C, more preferably between 40 ° C and 80 ° C, even more preferably between 45 and 65 ° C.
- the hydrogen pressure during the hydrogenation reaction of the compound of formula (VI) is preferably between 1 and 220 bar, more preferably between 1 and 100 bar, more preferably between 1 and 30 bar.
- the compounds of formula (VI) which are preferably used are the compounds of formula (VIa), in particular cases of the compounds of formula (VI) for which R 1 and R 2 together with the carbon atom which form carries them a 1,3-dioxane, 1,3-dioxolane or 1,3-dioxepane ring.
- the compounds of formula (I) are novel products, useful as synthesis intermediates in the chemical or pharmaceutical industry, in particular in the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid, and make it part of the present invention.
- the preferred compounds of formula (I) are those for which R 1 and R 2 together with the carbon atom carrying them form a 1,3-dioxane, 1,3-dioxolane or 1,3-dioxepane ring.
- MTBE tert-butyl ethyl ether
- the expected product is obtained with a yield of 88%, and a chemical purity greater than 98%.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0403828A FR2868775B1 (fr) | 2004-04-13 | 2004-04-13 | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR0403828 | 2004-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005111027A1 true WO2005111027A1 (fr) | 2005-11-24 |
Family
ID=34941961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/000396 WO2005111027A1 (fr) | 2004-04-13 | 2005-02-21 | Nouveau procede de synthese de derives de la 1,3,4,5 tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Country Status (33)
Country | Link |
---|---|
US (1) | US7064200B2 (fr) |
EP (1) | EP1614687B1 (fr) |
JP (2) | JP4515933B2 (fr) |
KR (1) | KR100636499B1 (fr) |
CN (1) | CN100348585C (fr) |
AR (1) | AR047707A1 (fr) |
AT (1) | ATE448221T1 (fr) |
AU (1) | AU2005200884B2 (fr) |
BR (1) | BRPI0500590B8 (fr) |
CA (1) | CA2496712C (fr) |
CY (1) | CY1109740T1 (fr) |
DE (1) | DE602005017541D1 (fr) |
DK (1) | DK1614687T3 (fr) |
EA (1) | EA007743B1 (fr) |
EG (1) | EG25619A (fr) |
ES (1) | ES2336461T3 (fr) |
FR (1) | FR2868775B1 (fr) |
GE (1) | GEP20074136B (fr) |
HK (1) | HK1079777A1 (fr) |
HR (1) | HRP20100024T1 (fr) |
MA (1) | MA27598A1 (fr) |
MX (1) | MXPA05003696A (fr) |
MY (1) | MY140904A (fr) |
NO (1) | NO329861B1 (fr) |
NZ (1) | NZ538328A (fr) |
PL (1) | PL1614687T3 (fr) |
PT (1) | PT1614687E (fr) |
RS (1) | RS51232B (fr) |
SG (1) | SG116574A1 (fr) |
SI (1) | SI1614687T1 (fr) |
UA (1) | UA81773C2 (fr) |
WO (1) | WO2005111027A1 (fr) |
ZA (1) | ZA200501468B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011098582A2 (fr) | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Nouvelles formes de chlorhydrate d'ivabradine |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
KR101478855B1 (ko) | 2007-05-30 | 2015-01-02 | 인드-스위프트 래버러토리즈 리미티드 | 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법 |
CN102264689B (zh) | 2008-12-22 | 2014-12-31 | 新梅斯托克尔卡公司 | 制备伊伐布雷定的方法 |
FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
FR2956401B1 (fr) * | 2010-02-17 | 2012-02-03 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2971507B1 (fr) * | 2011-02-14 | 2013-01-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2993561B1 (fr) * | 2012-07-17 | 2014-10-31 | Servier Lab | Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels |
FR3003859B1 (fr) * | 2013-03-26 | 2015-03-13 | Servier Lab | "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine" |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0204349A2 (fr) * | 1985-06-01 | 1986-12-10 | Dr. Karl Thomae GmbH | Dérivés d'amines hétéroaromatiques, médicaments les contenant et procédé pour leur préparation |
EP0534859A1 (fr) * | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
DE3418270A1 (de) * | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3519735A1 (de) * | 1985-06-01 | 1986-12-04 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
-
2004
- 2004-04-13 FR FR0403828A patent/FR2868775B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-07 CA CA2496712A patent/CA2496712C/fr active Active
- 2005-02-15 SG SG200500770A patent/SG116574A1/en unknown
- 2005-02-17 US US11/060,043 patent/US7064200B2/en active Active
- 2005-02-18 AU AU2005200884A patent/AU2005200884B2/en active Active
- 2005-02-18 JP JP2005041810A patent/JP4515933B2/ja active Active
- 2005-02-18 CN CNB2005100542167A patent/CN100348585C/zh active Active
- 2005-02-18 ZA ZA2005/01468A patent/ZA200501468B/en unknown
- 2005-02-18 NO NO20050888A patent/NO329861B1/no unknown
- 2005-02-18 UA UAA200501524A patent/UA81773C2/uk unknown
- 2005-02-18 AR ARP050100586A patent/AR047707A1/es active IP Right Grant
- 2005-02-18 BR BRPI0500590A patent/BRPI0500590B8/pt active IP Right Grant
- 2005-02-18 MA MA28112A patent/MA27598A1/fr unknown
- 2005-02-18 MY MYPI20050621A patent/MY140904A/en unknown
- 2005-02-18 GE GEAP8647A patent/GEP20074136B/en unknown
- 2005-02-18 NZ NZ538328A patent/NZ538328A/en unknown
- 2005-02-19 KR KR1020050013860A patent/KR100636499B1/ko active IP Right Grant
- 2005-02-19 EG EG2005020086A patent/EG25619A/xx active
- 2005-02-21 DE DE602005017541T patent/DE602005017541D1/de active Active
- 2005-02-21 SI SI200530864T patent/SI1614687T1/sl unknown
- 2005-02-21 AT AT05290383T patent/ATE448221T1/de active
- 2005-02-21 ES ES05290383T patent/ES2336461T3/es active Active
- 2005-02-21 DK DK05290383.8T patent/DK1614687T3/da active
- 2005-02-21 PL PL05290383T patent/PL1614687T3/pl unknown
- 2005-02-21 WO PCT/FR2005/000396 patent/WO2005111027A1/fr active Application Filing
- 2005-02-21 EA EA200500240A patent/EA007743B1/ru unknown
- 2005-02-21 EP EP05290383A patent/EP1614687B1/fr active Active
- 2005-02-21 PT PT05290383T patent/PT1614687E/pt unknown
- 2005-02-21 RS RSP-2010/0006A patent/RS51232B/sr unknown
- 2005-04-07 MX MXPA05003696A patent/MXPA05003696A/es active IP Right Grant
- 2005-12-22 HK HK05111843A patent/HK1079777A1/xx unknown
-
2009
- 2009-09-25 JP JP2009220529A patent/JP5277130B2/ja active Active
-
2010
- 2010-01-13 HR HR20100024T patent/HRP20100024T1/hr unknown
- 2010-01-19 CY CY20101100053T patent/CY1109740T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0204349A2 (fr) * | 1985-06-01 | 1986-12-10 | Dr. Karl Thomae GmbH | Dérivés d'amines hétéroaromatiques, médicaments les contenant et procédé pour leur préparation |
EP0534859A1 (fr) * | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011098582A2 (fr) | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Nouvelles formes de chlorhydrate d'ivabradine |
EP2902384A1 (fr) | 2010-02-12 | 2015-08-05 | KRKA, D.D., Novo Mesto | Formes de chlorhydrate d'ivabradine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1614687B1 (fr) | Nouveau procédé de synthèse de dérivés de la 1,3,4,5-tétrahydro-2H-3-benzazépin-2-one, et application à la synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
CA2496723C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
EP1598333B1 (fr) | Procédé de synthèse du (1S)-4,5-diméthoxy-1-(méthylaminométhyl)-benzocyclobutane et de ses sels d'addition, et application à la synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
EP2202225B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquemenet acceptable | |
EP1564202A1 (fr) | Nouveau procédé de synthèse et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent | |
CA2750089C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
CA2773064C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
EP1589014B1 (fr) | Procédé de synthèse de dérives de la 1,3-dihydro-2H-3-benzazepin-2-one et application à la synthèse de l'ivabradine et des sels d'addition à un acide pharmaceutiquement acceptable | |
EP2487158B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
WO2014013179A1 (fr) | Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels | |
WO2014087110A1 (fr) | Procédé de synthèse d'un sel d'addition a un acide pharmaceutiquement acceptable du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, ainsi que les formes cristallines associees | |
FR2984320A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
FR2988720A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |